
MaaT Pharma Secures €37.5M EIB Loan to Advance Hemato-Oncology Program
MaaT Pharma Secures €37.5 Million EIB Loan to Propel Hemato-Oncology Pipeline and Microbiome Therapy Leadership MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotechnology company pioneering Microbiome Ecosystem Therapies™ (MET) to improve survival outcomes in cancer patients through immune modulation, announced a…